These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 15262123)

  • 41. [Comparative clinical appraisal of the effectiveness and tolerability of paclitaxel-LANCE and taxol in combination chemotherapy for recurrences and platinum-refractory ovarian carcinoma].
    Gershanovich ML; Makhnova EV; Livshits ME; Gulo EI
    Vopr Onkol; 2004; 50(6):716-9. PubMed ID: 15755070
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Kallikrein-related peptidase 7 promotes multicellular aggregation via the alpha(5)beta(1) integrin pathway and paclitaxel chemoresistance in serous epithelial ovarian carcinoma.
    Dong Y; Tan OL; Loessner D; Stephens C; Walpole C; Boyle GM; Parsons PG; Clements JA
    Cancer Res; 2010 Apr; 70(7):2624-33. PubMed ID: 20332224
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
    Zhao XD; Zhang Q; Zhang Y
    Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of paclitaxel on CA-125 serum levels in ovarian cancer patients.
    Paulsen T; Marth C; Kaern J; Nustad K; Kristensen GB; Tropé C
    Gynecol Oncol; 2000 Mar; 76(3):326-30. PubMed ID: 10684705
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Compartmentalized expression of kallikrein 4 (KLK4/hK4) isoforms in prostate cancer: nuclear, cytoplasmic and secreted forms.
    Dong Y; Bui LT; Odorico DM; Tan OL; Myers SA; Samaratunga H; Gardiner RA; Clements JA
    Endocr Relat Cancer; 2005 Dec; 12(4):875-89. PubMed ID: 16322328
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study.
    Pignata S; Ferrandina G; Scarfone G; Scollo P; Odicino F; Cormio G; Katsaros D; Frigerio L; Mereu L; Ghezzi F; Manzione L; Lauria R; Breda E; Alletti DG; Ballardini M; Vernaglia A; Sorio R; Tumolo S; Musso P; Magni G; Pisano C; Morabito A
    Crit Rev Oncol Hematol; 2009 Sep; 71(3):233-41. PubMed ID: 19179095
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Expression and prognostic significance of kallikrein-related peptidase 8 protein levels in advanced ovarian cancer by using automated quantitative analysis.
    Kountourakis P; Psyrri A; Scorilas A; Markakis S; Kowalski D; Camp RL; Diamandis EP; Dimopoulos MA
    Thromb Haemost; 2009 Mar; 101(3):541-6. PubMed ID: 19277417
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The "Leuven" dose-dense paclitaxel/carboplatin regimen in patients with recurrent ovarian cancer.
    Cadron I; Leunen K; Amant F; Van Gorp T; Neven P; Vergote I
    Gynecol Oncol; 2007 Aug; 106(2):354-61. PubMed ID: 17499348
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.
    Gershenson DM; Sun CC; Bodurka D; Coleman RL; Lu KH; Sood AK; Deavers M; Malpica AL; Kavanagh JJ
    Gynecol Oncol; 2009 Jul; 114(1):48-52. PubMed ID: 19361839
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Immunohistochemical expression of integrin alphav, beta5 and beta3 in ovarian epithelial carcinoma: correlation with drug resistance of chemotherapy].
    Guo HY; Han JS; Zhang LF; Wang LN; Geng L; Chen GA
    Zhonghua Fu Chan Ke Za Zhi; 2004 Nov; 39(11):750-3. PubMed ID: 15634501
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Weakened spindle checkpoint with reduced BubR1 expression in paclitaxel-resistant ovarian carcinoma cell line SKOV3-TR30.
    Fu Y; Ye D; Chen H; Lu W; Ye F; Xie X
    Gynecol Oncol; 2007 Apr; 105(1):66-73. PubMed ID: 17234259
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells.
    Okamoto A; Nikaido T; Ochiai K; Takakura S; Saito M; Aoki Y; Ishii N; Yanaihara N; Yamada K; Takikawa O; Kawaguchi R; Isonishi S; Tanaka T; Urashima M
    Clin Cancer Res; 2005 Aug; 11(16):6030-9. PubMed ID: 16115948
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clusterin confers paclitaxel resistance in cervical cancer.
    Park DC; Yeo SG; Shin EY; Mok SC; Kim DH
    Gynecol Oncol; 2006 Dec; 103(3):996-1000. PubMed ID: 16890274
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer.
    Borgoño CA; Kishi T; Scorilas A; Harbeck N; Dorn J; Schmalfeldt B; Schmitt M; Diamandis EP
    Clin Cancer Res; 2006 Mar; 12(5):1487-93. PubMed ID: 16533772
    [TBL] [Abstract][Full Text] [Related]  

  • 55. P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel- plus platinum-based chemotherapy and long-term clinical outcome.
    Gadducci A; Di Cristofano C; Zavaglia M; Giusti L; Menicagli M; Cosio S; Naccarato AG; Genazzani AR; Bevilacqua G; Cavazzana AO
    Anticancer Res; 2006; 26(1B):687-93. PubMed ID: 16739339
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer.
    Linch M; Stavridi F; Hook J; Barbachano Y; Gore M; Kaye SB
    Gynecol Oncol; 2008 Apr; 109(1):27-32. PubMed ID: 18262259
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study.
    ; Secord AA; Lee PS; Darcy KM; Havrilesky LJ; Grace LA; Marks JR; Berchuck A
    Gynecol Oncol; 2006 Jun; 101(3):390-7. PubMed ID: 16551475
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806.
    Rincon M; Broadwater G; Harris L; Crocker A; Weaver D; Dressler L; Berry D; Sutton L; Michaelson R; Messino M; Kirshner J; Fleming G; Winer E; Hudis C; Appel S; Norton L; Muss H;
    Breast Cancer Res Treat; 2006 Dec; 100(3):301-8. PubMed ID: 16773437
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel-containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group.
    Fotopoulou C; duBois A; Karavas AN; Trappe R; Aminossadati B; Schmalfeldt B; Pfisterer J; Sehouli J;
    J Clin Oncol; 2008 Jun; 26(16):2683-9. PubMed ID: 18509180
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nonlinear pharmacokinetics of paclitaxel in ovarian cancer patients.
    Ye M; Zhu Z; Fu Q; Shen K; Li DK
    Acta Pharmacol Sin; 2000 Jul; 21(7):596-9. PubMed ID: 11360664
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.